The AMP-activated protein kinase (AMPK) is a heterotrimeric protein complex that is an important sensor of cellular energy status. Reduced expression of the AMPK b1 isoform has been linked to reduced survival in different cancers, but whether this accelerates tumor progression and the potential mechanism mediating these effects are not known. Furthermore, it is unknown whether AMPK b1 is implicated in tumorigenesis, and if so, what tissues may be most sensitive. In the current study, we find that in the absence of the tumor suppressor p53, germline genetic deletion of AMPK b1 accelerates the appearance of a T-cell lymphoma that reduces lifespan compared to p53 deficiency alone. This increased tumorigenesis is linked to increases in interleukin-1b (IL1b), reductions in acetyl-CoA carboxylase (ACC) phosphorylation, and elevated lipogenesis. Collectively, these data indicate that reductions in the AMPK b1 subunit accelerate the development of T-cell lymphoma, suggesting that therapies targeting this AMPK subunit or inhibiting lipogenesis may be effective for limiting the proliferation of p53-mutant tumors.
Introduction
While it is now established that obesity and diabetes can increase the risk of developing many types of cancer, the molecular signals that collaborate with oncogenes to accelerate tumorigenesis under conditions of nutrient excess are still not fully understood. The AMP-activated protein kinase (AMPK) is an a, b, c heterotrimer that senses changes in cellular energy status, and whose activity is reduced under conditions of nutrient surplus such as obesity and diabetes (Ruderman et al., 2013; Steinberg and Kemp, 2009) . AMPK activation by the upstream AMPK kinase LKB1 causes regulation of multiple branches of cellular metabolism that may be important for limiting cancer cell proliferation (Mihaylova and Shaw, 2011) . This involves the inhibition of energy-consuming processes such as fatty acid and protein biosynthesis, while increasing catabolism by promoting autophagy and fatty acid oxidation (Carling et al., 2012; Faubert et al., 2015; Mihaylova and Shaw, 2011) . In addition to direct regulation of key metabolic checkpoints, AMPK may also inhibit tumorigenesis through upregulation of transcription factors such as the tumor suppressor p53, which is mutated in approximately 80% of all cancers (He et al., 2014; Jones et al., 2005; Lee et al., 2012) . Mutation or genetic deficiency of p53 may also act to suppress AMPK activity (Zhou et al., 2014) , suggesting that the activities of p53 and AMPK may be intimately linked to match energy availability with cell proliferation (Adamovich et al., 2014) . While many studies have examined the interaction between AMPK and the tumor suppressor p53 in cultured cells, the importance of this pathway to tumorigenesis has not been studied in vivo.
Increases in fatty acid synthesis are required to sustain rapid proliferation in many types of cancer [for review, see (Hanahan and Weinberg, 2011; Hirschey et al., 2015) ] including prostate and non-small-cell lung cancer (NSCLC) (Shah et al., 2016; Svensson et al., 2016; Villani et al., 2016) . Rates of fatty acid synthesis are governed by the expression of ATP-citrate lyase (ACLY), acetyl-CoA carboxylase (ACC), and fatty acid synthase (FAS) (Hanahan and Weinberg, 2011; Hirschey et al., 2015; Shah et al., 2016; Svensson et al., 2016; Villani et al., 2016) . While AMPK may regulate multiple branches of the lipogenic pathway, direct phosphorylation of ACC has been shown to result in the inhibition of ACC activity, thereby preventing the conversion of acetyl-CoA to malonyl-CoA and blocking the entire lipogenic program (Fullerton et al., 2013; Munday et al., 1988) . As such, AMPK may exert antiproliferative effects through both inhibition of lipogenesis and by inhibiting cell cycle progression.
Despite the many connections between AMPK and cancer cell proliferation, mutations in the AMPK b1 subunit are not common in cancers (Forbes et al., 2015) and recent studies have suggested that inhibition of AMPK may make cancer cells more sensitive to apoptosis (Jeon et al., 2012; Shackelford et al., 2013; Zadra et al., 2015) . Thus far, only one study has examined the effects of germline deletion of AMPK in a mouse model of tumorigenesis where the authors observed that deletion of the AMPK a1 isoform promoted B-cell lymphoma when crossed to c-Myc transgenic mice (Faubert et al., 2013) . To the best of our knowledge, the in vivo importance of other AMPK subunits in combination with genetic loss of tumorsuppressing pathways has not been studied. However, this is important given that the 12 different AMPK heterotrimer combinations have unique tissue-specific expression, enzyme activities, and substrates (Ross et al., 2016) and may have differential effects in distinct settings of oncogenesis (i.e., when interacting with distinct tumor-promoting pathways).
The AMPK b1 isoform plays a vital role in regulating AMPK heterotrimer formation and enzyme activity in mouse liver and hematological cells such as macrophages and T cells where it increases fatty acid oxidation, suppresses fatty acid synthesis, and inhibits inflammatory pathways Dzamko et al., 2010; Fullerton et al., 2015; Galic et al., 2011) . It is also the primary subunit which is targeted by small-molecule direct AMPK activators such as A769662 (Cool et al., 2006; Sanders et al., 2007; Scott et al., 2014) , MT-63-78 (Zadra et al., 2014) , and salicylate (Hawley et al., 2012) , all of which have been shown to reduce cancer cell proliferation in some (Huang et al., 2008; O'Brien et al., 2015; Zadra et al., 2014) , but not all studies . Elevated AMPK b1 expression has also been linked to increased lymphoma (Hoffman et al., 2013) and ovarian cancer survival (Li et al., 2012) , tumor types that are commonly associated with mutations in p53. In addition the DNA-damaging agent etoposide increases AMPK b1 expression and overexpression of AMPK b1 reduces cellular proliferation in vitro (Li et al., 2003) . However, it is not known whether AMPK b1 can inhibit tumorigenesis in vivo and in what tissues/ tumor types this may be most important.
In the current study, we generated AMPK b1-p53 null mice and found that this combined genotype accelerates the development of a lethal T-cell lymphoma compared to p53 deletion alone. This increased lethality is linked with reductions in tumor ACC phosphorylation and increases in interleukin 1b and lipid synthesis. These data indicate that AMPK b1 containing complexes and AMPK activity may be important to limit tumorigenesis and improve survival in p53deficient T-cell lymphomas.
Results

The genetic deletion of AMPK b1 accelerates the development of T-cell lymphoma in p53deficient mice
To investigate the connections between AMPK and p53 in vivo, we crossed AMPK b1 null mice (Dzamko et al., 2010) to mice lacking p53 (Donehower et al., 1992) . AMPK b1 null mice (Dzamko et al., 2010) were generated on a C57Bl6 background as described and p53 null mice had been backcrossed to a C57Bl6 background for at least 10 generations. Genetic deletion of p53 results in the development of a T-cell lymphoma at approximately 6 months of age (Jacks et al., 1994) . In contrast, AMPK b1 null mice have a normal lifespan with no signs of elevated tumorigenesis (Dzamko et al., 2010) . The AMPK b1À/À mice were born at the expected Mendelian ratio (Fig. S1 ). In contrast, the homozygous p53À/À mice were born at a lower Mendelian frequency (Fig. S1 ). In order to generate the p53À/À AMPK b1À/À mice, we then crossed and interbred, as described in Fig. S1 , the different mice genotypes.
Lifespan of mice was monitored over time by animal technicians in a blinded manner. At 3 months of age, we assessed in situ [ 18 F]fluorodeoxyglucose (FDG) uptake using positron emission tomography/computed tomography (PET/CT) imaging and found that there was a tendency for p53À/À AMPK b1À/À mice to have increases in thymic FDG uptake compared to p53À/À AMPK b1+/+ mice ( Fig. 1A ), suggesting earlier tumor onset in p53À/À AMPK b1À/À compared to p53À/À AMPK b1+/+ mice. Consistent with earlier tumor onset, mice heterozygous for p53 (p53+/À) or homozygous for p53 (p53À/À) in the absence of AMPK b1 had reduced survival ( Fig. 1B,C) . These data indicate that AMPK b1 is important for limiting tumor development and lethality following homozygous or heterozygous deletion of the tumor suppressor p53.
At endpoint (which was earlier in the p53À/À AMPK b1À/À compared to p53À/À AMPK b1+/+ mice), pathological analysis indicated that both genotypes developed a similar tumor in the thymus ( Fig. 2A) . The size and weight of these tumors was not different between genotypes at endpoint ( Fig. 2A ). Both genotypes also developed a much smaller proportion other tumors that match the tumor spectrum observed in the p53À/À mice (Table 1) (Jacks et al., 1994) . p53 null mice are known to develop A B C Fig. 1 . Accelerated tumor progression in the p53À/À AMPK b1À/À mice. (A) Three-month-old mice were submitted to CT/PET scan, and thymic 18 F-FDG uptake was then quantified for the p53À/À AMPK b1+/+ and p53À/À AMPK b1À/À mice. SUV, standardized uptake values. n = 5-6 per genotypes. Results are the means AE SEM *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 using two-tailed Student's t-test. (B) Kaplan-Meier survival curve showing survival of the p53+/À AMPK b1+/+ (blue) and p53+/À AMPK b1À/À (green) mice (*P < 0.05 by Wilcoxon test). n = 6-11 mice per group. C) Kaplan-Meier survival curve showing survival of the p53À/À AMPK b1+/+ (black) and p53À/À AMPK b1À/À (red) mice (*P < 0.05 by Wilcoxon test). n = 13-14 mice per group. thymic T-cell lymphomas (Donehower et al., 1992; Jacks et al., 1994) . Therefore, we next examined two markers of T cells (CD3 and FoxP3) and found that expression levels were similar in the tumors of p53À/À AMPK b1+/+ and 53À/À AMPK b1À/À mice ( Fig. 2B ). Confirming these findings, immunohistochemical (IHC) staining of tumor sections indicated similar expression of the T-cell marker CD3 (Fig. 2C ). Collectively, these findings suggest that genetic deletion of AMPK b1 does not change the tumor spectrum but rather accelerates tumor progression.
AMPK b1 deficiency reduces ACC phosphorylation and accelerates lipogenesis
We performed immunoblot analysis of tumor protein extracts collected at endpoint and found that p53À/À AMPK b1À/À tumors had large reductions in total AMPK a expression and AMPK activating phosphorylation at Thr172 ( Fig. 3A -C). As anticipated, there was no detectable p53, and importantly, there appeared to be no compensatory increase in AMPK b2 expression ( Fig. 3A) . These data indicate that tumors of p53À/À AMPK b1À/À mice had large reductions in AMPK activating phosphorylation.
AMPK may regulate tumorigenesis through multiple mechanisms so we examined phosphorylation of key downstream substrates. One way AMPK may inhibit tumorigenesis is through phosphorylation of ULK1 at Ser555 and subsequent upregulation of autophagy (Mihaylova and Shaw, 2011) . There was a tendency for a reduced ratio of pULK1 S555 to ULK1 in tumors of p53À/À AMPK b1À/À mice (Fig. S2A,B ). However, there were no other signs of dysregulated autophagy as inhibitory phosphorylation of ULK1 S757/ULK1 (Fig. S2A,C ( Fig. S2A ,D) and ATG13 ( Fig. S2A,E) , and the ratio of LC3BII to LC3BI ( Fig. S2F ,G) were all comparable between genotypes. AMPK may also limit tumorigenesis by inhibiting mTOR activity (Mihaylova and Shaw, 2011) , but we found that three downstream markers of mTOR activity (S6K1 and S6 kinases and HIF1a) were similar between genotypes ( Fig. S3A-C) . Activating phosphorylation of Akt was also unaltered (Fig. S3A ,D-E). As mitochondrial content is regulated by AMPK and has emerged as an important factor regulating tumor progression (Hirschey et al., 2015) , we measured components of the electron transport chain and found that they were also comparable between p53À/À AMPK b1+/+ and p53À/À AMPK b1À/À mice, suggesting that tumor mitochondrial content was not altered (Fig. S3A,F) . These data suggest reductions in autophagy and mitochondrial content or increases in Akt and mTOR did not contribute to the increased tumor progression in p53À/À AMPK b1À/À mice. As AMPK b1 is important for inhibiting inflammation (Galic et al., 2011) and inflammation can accelerate lymphoma development (Grivennikov et al., 2011) , we measured the mRNA and protein expression of inflammatory cytokines. We found that the mRNA and protein expression of inflammatory markers were not altered with the exception of IL1b protein which was elevated in tumors of p53À/À AMPK b1À/À mice (Table S1 ). However, this increase in IL1b was not accompanied by elevated activating phosphorylation of c-Jun N-terminal kinase (JNK), which is known to be downstream of the IL1 receptor ( Fig. S3A,G) . There was also no difference in the activating phosphorylation (S727 or Y705) of the signal transducer and activator of transcription 3 (STAT3) ( Fig. S3A ,H,I).
Elevated rates of lipogenesis are used to fuel membrane biosynthesis in rapidly proliferating cells (Menendez and Lupu, 2007; Zadra et al., 2014) . ACC is an important enzyme regulating lipogenesis and is inhibited by AMPK following phosphorylation at Ser79 (Fullerton et al., 2013; Munday et al., 1988) . We found that consistent with reductions in AMPK activating phosphorylation, there was a reduction of approximately 50% in phosphorylation of ACC at Ser79 compared to the p53À/À AMPK b1+/+ tumors ( Fig. 4A,B ). There were no alterations in the expression of other lipogenic enzymes [acetyl-CoA synthetase (ACCSS2), malonyl-CoA decarboxylase (MCD), ATPcitrate lyase (ACLY), fatty acid synthase (FASN), and phosphorylation of S372 on sterol regulatory elementbinding protein 1c (SREBP1c)]. Consistent with reductions in ACC phosphorylation, we measured in vivo lipogenesis in 3-month-old mice and found that p53À/À AMPK b1À/À mice tended to have an increased incorporation of acetate into fatty acids compared to p53À/À AMPK b1+/+ mice (Fig. 4C) . These data indicate that genetic deletion of AMPK b1 leads to reductions in ACC phosphorylation and tends to increase de novo lipogenesis in vivo.
To further examine the mechanisms by which lipogenesis may regulate cellular proliferation, we generated mouse embryonic fibroblasts (MEFs) from p53À/À AMPK b1+/+ and p53À/À AMPK b1À/À littermates. Consistent with immunoblotting in tumors, we found that p53À/À AMPK b1À/À MEFs (Fig. 4D ) had reductions in AMPK and ACC phosphorylation ( Fig. 4D-G) , but not alterations in the expression of other regulators of lipogenesis (ACSS2, MCD, ACLY, FASN, pSREBP1c, Fig. 4D ). Similar to observations in the tumor, this reduction in ACC phosphorylation was associated with a significant A B C Fig. 3 . Impaired AMPK phosphorylation in tumors harvested from the p53À/À AMPK b1À/À mice. (A) Tumors harvested from p53À/À AMPK b1+/+ and p53À/À AMPK b1À/À mice were homogenized and subjected to immunoblotting using the indicated antibodies. Six animals per genotype are shown. A thymus from a WT mouse was used as a control. Bar graphs show densitometry of (B) AMPKa/b-actin, C) pAMPKa Thr172/b-actin. Results are the means AE SEM. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 using two-tailed Student's t-test. increase in lipogenesis (Fig. 4H) . These data suggest that reduced AMPK-mediated phosphorylation of ACC was important for increasing lipogenesis and the subsequent proliferative capacity of p53À/À AMPK b1À/À mice via a cell autonomous pathway.
To directly evaluate the importance of AMPK phosphorylation of ACC in regulating cellular proliferation, we examined MEFs derived from mice with Ser-Ala-knock-in mutations in the AMPK phosphorylation site on ACC1 (S79A) and ACC2 (S212A) (ACC DKI), which makes ACC constitutively active and increases rates of lipogenesis (Fullerton et al., 2013) . We found that MEFs derived from ACC DKI mice had increased proliferation rates by 1.9-fold compared to WT controls (Fig. 4I) , indicating that AMPK regulation of ACC phosphorylation is vital for limiting cellular proliferative capacity. To further examine the importance of lipogenesis in regulating cellular proliferation, we treated MEFs with TOFA and C75, two inhibitors of lipogenesis that act downstream of AMPK b1 to inhibit ACC and fatty acid synthase activity, respectively, and found that both agents dose dependently inhibited cellular proliferation (Fig. 4J,K) . Collectively, these data suggest that AMPK b1 inhibition of lipogenesis, through phosphorylation of ACC, may be important for limiting proliferation in the absence of p53.
Discussion
Reductions in AMPK activity can occur under a number of pathological conditions known to increase cancer incidence. These include inactivating mutations in the tumor suppressors p53 and LKB1 or elevated levels of glucose (Friedrichsen et al., 2013) , insulin (Ruderman et al., 2013) , TNF (Steinberg et al., 2006) , and LPS (Galic et al., 2011) . In contrast, elevated levels of AMPK b1 have been associated with increased survival in lymphoma and ovarian cancer (Hoffman et al., 2013; Li et al., 2012) . In the current study, we provide the first genetic evidence that deletion of the AMPK b1 isoform accelerates the progression of a T-cell lymphoma that reduces the survival of mice that are heterozygous or homozygous null for p53. Interestingly, the deletion of AMPK b1 did not alter the spectrum of cancer development compared to p53 deficiency alone, in that both mice still developed T-cell lymphoma. This may be because AMPK b1 is the predominant subunit expressed in the thymus and hematopoietic tissues and hence these tissues, which are also the most sensitive to the loss of p53, also had the greatest reduction in AMPK activity. While our findings may only be applicable to T-cell lymphoma, it is intriguing to speculate that because p53 loss-of-function mutations are associated with approximately 80% of all cancers, these findings may be applicable to other types of cancer where the AMPK b1 subunit predominates, such as the liver, lung, gastrointestinal tract, or ovaries.
Previous studies by Faubert et al. (2013) found that genetic deletion of AMPK a1 accelerates Myc-driven lymphoma due to elevations in mTORC1 activity and subsequent increases in HIF1a that promoted aerobic glycolysis (Warburg effect). In contrast to these findings, we found that AMPK b1-p53 null tumors did not have altered activity of mTORC1 (as detected by normal phosphorylation of downstream substrates S6K, S6, and ULK1 S757) or HIF1a. We also detected no change in markers of autophagy or mitochondrial content. Instead, we found that AMPK b1 p53 null tumors and MEFs had increased rates of lipogenesis that was not associated with alterations in the expression of fatty acid synthetic enzymes but instead was directly related to reduced phosphorylation of ACC. Proliferation data from the ACC DKI MEFs or cells treated with lipogenesis inhibitors corroborated these results, suggesting that AMPK control of lipogenesis, through ACC inhibition, is important for limiting cellular proliferation. These data are in agreement with previous studies indicating that hepatocytes (Dzamko et al., 2010) and macrophages from AMPK b1-deficient mice have increased lipid synthesis and that activation of AMPK using A769662 or metformin lowers lipogenesis through an AMPK b1-dependent pathway requiring the phosphorylation of ACC (Fullerton et al., 2013) . These data are also consistent with recent studies indicating that inhibiting lipogenesis, by mimicking AMPK phosphorylation of ACC using small molecules (Svensson et al., 2016) or through chemical inhibition of fatty acid synthase (Menendez and Lupu, 2007; Orita et al., 2008) , is effective for limiting cellular proliferation. However, it is possible that the inhibition of proliferation is not directly related to the blunting of lipid synthesis but rather a buildup of malonyl-CoA or some other metabolite. Furthermore, under conditions of metabolic stress that are common within the tumor microenvironment, it is possible that increases in lipid synthesis may be toxic for tumor survival as previously described (Jeon et al., 2012) . Future studies in mice lacking p53 and ACC1 S79 and ACC2 S212 phosphorylation are required to directly establish the importance of this lipogenic pathway in limiting proliferation and survival.
In addition to increases in lipogenesis, we also detected elevated IL1b protein (but not other inflammatory proteins) in AMPK b1p53 null tumors. In contrast to other inflammatory cytokines (e.g., TNFa, IL6), increases in IL1b protein are the result of the induction of the NLRP3 (NOD-like receptor family, pyrin domain containing) inflammasome pathway (Haneklaus et al., 2013; Steinberg and Schertzer, 2014) . Production of bioactive IL1b by the NLRP3 inflammasome requires a two-step process involving initial priming from the toll-like receptors (TLR) by lipopolysaccharide (LPS) and subsequent activation by hyperglycemia, saturated fatty acids such as palmitate, ROS, oxidized LDL, or cholesterol crystals. This leads to NLRP3 assembly with a protein complex containing caspase-1 and consequent processing and secretion of mature IL1b (Haneklaus et al., 2013; Steinberg and Schertzer, 2014) . Importantly, the NLRP3 inflammasome can be inhibited by AMPK (Wen et al., 2011) , although the mechanisms are not fully understood [for review, see (Steinberg and Schertzer, 2014) ]. So while the role of IL1b in tumorigenesis is context dependent and is largely dependent on the tumor microenvironment, it is possible that AMPK inhibition of the NLRP3 inflammasome may also be important for reducing tumorigenesis in p53 null mice. However, future studies are required to directly investigate this concept.
Our study had several limitations. First, we did not examine the morphology of tumors before endpoint. Earlier analysis of tumors could have potentially led to detectable differences in signaling pathways, histology, and tumor sizes between genotypes. Consistent with this idea, there were strong tendencies for increases in both FDG uptake and lipogenesis in p53À/À AMPK b1À/À mice at 12 weeks of age, which was 6-10 weeks before endpoint. Another limitation of our study was that we did not examine the effects of AMPK b1 deletion specifically in T cells. This means that increases in tumorigenesis and reduced survival in p53À/À AMPK b1À/À could have been due to other factors besides the primary lesion. For example, AMPK a1, b1, and c1 null mice have been shown to have increased red blood cell fragility, which causes microcytic anemia and splenomegaly without altering the number of leukocytes (Cambridge et al., 2017; F€ oller et al., 2009; Foretz et al., 2010 Foretz et al., , 2011 . We also observed splenomegaly in our AMPK b1 null mice (Table S2 ) so it is possible that this could have an impact on tumorigenesis and lifespan of p53À/À AMPK b1À/À mice. Future studies investigating deletion of AMPK b1 and p53 specifically in T cells will be important for establishing the exact tissues contributing to the accelerated tumorigenesis and reduced longevity of p53À/À AMPK b1À/À mice.
In conclusion, our studies provide the first in vivo evidence for a role of the AMPK b1 isoform in limiting the progression of tumorigenesis that results from a deficiency in p53. Increased tumorigenesis in this model was associated with reduced AMPK phosphorylation of ACC and elevated IL1b and lipogenesis, indicating that the maintenance of AMPKb1 expression is important for limiting the progression of p53-deficient tumors.
Materials and methods
Materials
Complete protease inhibitor cocktail tablets were obtained from Roche (Laval, QC, Canada). [ 3 H]Acetic acid was from PerkinElmer (Waltham, MA, USA). Cell culture media and reagents were from Life Technologies (Burlington, ON, Canada). TOFA (5-(tetradecyloxy)-2-furoic acid) and C75 ((2R*,3S*)-tetrahydro-4-methylene-2-octyl-5-oxo-3-furancarboxylic acid) were purchased from Cayman Chemical (Ann Arbor, MI, USA). All other chemicals were purchased from Sigma (St. Louis, MO, USA).
Antibodies
The anti-phospho-ACC S79 (catalogue # 3661), anti-ACC (catalogue # 3676), anti-phospho-AMPKa Thr172 (catalogue # 2535), anti-AMPKa (catalogue # 2532), anti-AMPK b1/b2 (catalogue # 4150), anti-p53 (catalogue # 2524), anti-b-actin (catalogue # 5125), anti-acetyl-CoA synthetase (ACSS2) (catalogue # 3658), anti-pULK1 S555 (catalogue # 5569), antiphospho-ULK1 S757 (catalogue # 6888), anti-ULK1 (catalogue # 8054), anti-p62 (catalogue # 5114), anti-ATG13 (catalogue # 6940), anti-LC3B (catalogue # 3868), anti-phospho-S6K1 Thr389 (catalogue # 9205), anti-S6K1 (catalogue # 9202), anti-phospho-S6 S240/244 (catalogue # 5364), anti-S6 (catalogue # 2217), anti-phospho-Akt S473 (catalogue # 4058), anti-phospho-Akt Thr308 (catalogue # 4056), anti-Akt (catalogue # 9272), anti-ATP-citrate lyase (ACLY) (catalogue # 4332), anti-fatty acid synthase (Fasn) (catalogue # 3189), anti-phospho-sterol regulatory element-binding protein 1c-S372 (SREBP1c) (catalogue # 9874), anti-HIF1a (catalogue # 3716), anti-phospho-c-Jun N-terminal kinase Thr183/Y185 (JNK) (catalogue # 4668), anti-phospho-signal transducer and activator of transcription 3 S727 (STAT3) (catalogue # 9134), and anti-phospho-STAT3 Y705 (catalogue # 9145) were purchased from Cell Signaling Technology (Danvers, MA, USA). Malonyl-CoA decarboxylase (MCD) (catalogue # ab95945) antibody was purchased from Abcam (Cambridge, MA, USA) . The anti-CD3 (MRQ-39) antibody used for immunohistochemistry was from CELL MARQUE (Rocklin, CA, USA). The anti-OXPHOS antibody was purchased from MitoSciences (Eugene, OR, USA). The anti-secondary antibodies coupled to HRP (horseradish peroxidase) were from Cell Signaling Technology.
Generation of p53À/À AMPK b1À/À mice
All experiments were approved by the McMaster University Animal Ethics Committee and conducted under the Canadian guidelines for animal research. Animals were housed in microisolator cages located in a room maintained at 23°C with a 12-h light/dark cycle and fed with normal chow diet ad libitum. p53+/À mice on a C57BL/6 background were purchased from The Jackson Laboratory (B6.129S2-Trp53 tm1Tyj/J , stock 002101; Bar Harbor, ME, USA). AMPK b1 null mice (Dzamko et al., 2010) were generated on a C57Bl6 background as described and p53 null mice had been backcrossed to a C57Bl6 background for at least 10 generations. Heterozygous mice (p53+/À) were interbred to generate p53À/À and p53+/+ littermates. The p53À/À mice were then crossed with the AMPK b1À/À mice (Dzamko et al., 2010) to generate the p53+/À AMPK b1+/À mice. These mice were then interbred to generate the p53À/ À AMPK b1À/À mice on a C57Bl6 background. Lifespan was determined in a blinded manner by an animal technician who monitored whether mice were found dead or whether mice had reached endpoint according to established parameters [weight loss (>20%), hunched posture, lethargy, labored breathing]. Routine pathology analysis of formalin-fixed tissues harvested from mice culled at endpoint was performed at the Department of Pathobiology, Ontario Veterinary College, University of Guelph (Ontario, Canada).
Generation of MEFs
p53À/À AMPK b1+/+, p53À/À AMPK b1À/À, and ACC DKI (S79A in ACC1 and S212A in ACC2) MEFs isolated from mouse embryos at E13.5 (embryonic day 13.5) were generated as described previously (Houde et al., 2014) and immortalized by continuous passaging. Cells were cultured in DMEM (25 mM glucose) containing 10% FBS, 4 mM Lglutamine, 1 mM sodium pyruvate, 1X antibiotic/antimycotic solution, and 1X nonessential amino acids solution.
Mouse imaging
[ 18 F]Fluorodeoxyglucose (FDG) was synthesized at McMaster University and injected into threemonth-old male mice as previously described (Palanivel et al., 2012) . FDG uptake was quantified as described (Crane et al., 2015) . 4.6. Cell proliferation 5 9 10 2 cells per well were seeded on 96-well plate and grown for 5 days before being fixed with 10% formalin, stained with 0.5% crystal violet, washed with H 2 O, and dried at 37°C. The crystal violet was then solubilized with 0.05 M NaH 2 PO 4 and the absorbance measured at 570 nm as described (O'Brien et al., 2015) . Proliferation rate was compared from untreated p53+/+ AMPK b1+/+ and ACC DKI MEFs. p53À/À AMPK b1À/À MEFs were also treated with TOFA and C75 at the indicated concentrations 24 h after seeding, and proliferation was monitored as described above.
Immunoblotting
Cells were washed with PBS and lysed in ice-cold lysis buffer (20 mM Tris/HCl, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 2.5 mM Na 4 O 7 P 2 , 1 mM Na 3 VO 4 , and Roche inhibitor cocktail). Tissues were homogenized on ice using a Polytron in a 10-fold mass excess of ice-cold lysis buffer. Lysates were clarified by centrifugation at 19 000 g for 15 min at 4°C. Protein concentrations were measured with a BCA assay. Tissue or cell lysates (10-20 lg) were heated in SDS sample buffer and subjected to SDS/PAGE followed by electrotransfer on to nitrocellulose membranes. Membranes were blocked in TBST [50 mM Tris/HCl (pH 7.5), 0.15 mM NaCl, and 0.1% Tween] containing 5% BSA for 1 h. The membranes were then probed with the primary antibody (1000-fold dilution) for 16 h at 4°C in TBST 5% BSA. Detection of protein was performed using HRP-conjugated secondary antibodies and an ECL reagent. Immunoblots were analyzed using IMAGEJ software (NIH, Bethesda, MD, USA).
Measurement of lipogenesis
In vitro, cells were labeled for 4 h with 0.5 mM sodium acetate and 10 lCi mL À1 [ 3 H]acetic acid in growth media. Cells were washed three times with ice-cold PBS and then scraped into chilled PBS. Cells were pelleted by centrifugation at 2000 g for 2 min. A methanol/chloroform lipid extraction was performed on the cell pellets. After the extraction, the insoluble material (pellet) was dissolved in 0.5 M NaOH/0.5% SDS in order to quantify the amount of protein per well. The incorporation of [ 3 H] into the lipid was measured by scintillation counting. The incorporation rate was defined in units of nmol of acetate/mg of protein/h.
In vivo, 12-week-old mice were fasted for 16 h and refed for 2 h. 20 lCi of [ 3 H]acetic acid was then injected intraperitoneally (IP) for 1 h. De novo lipogenesis was determined in vivo by the incorporation of [ 3 H]acetate into thymic lipids.
Immunohistochemistry lymphoma
Formalin-fixed and paraffin-embedded 5-lm sections were stained with hematoxylin and eosin or an anti-CD3 antibody (Pearse, 2006) , using BENCHMARK ULTRA VENTANA accordingly to the manufacturer's instructions (Roche).
mRNA expression
For mRNA analysis, tissues were lysed in TRIzol reagent (Life Technologies) and RNA was extracted for qRT-PCR and mRNA assessed as described (Galic et al., 2011) .
Enzyme-linked immunosorbent assay
Tumors (50-100 mg) were homogenized on ice using a Polytron in ice-cold lysis buffer 2 (catalogue # 895347, R&D Systems, Minneapolis, MN, USA) containing Roche inhibitor cocktail. Lysates were clarified by centrifugation at 19 000 g for 15 min at 4°C. Protein concentrations were measured with a BCA assay. 500 lg of protein lysate was then used to measure IFNc (Quantikine, R&D Systems), IL6, IL1b, and TNFa (DuoSet, R&D Systems) according to the manufacturer's instructions.
Statistical analysis
Results are expressed as mean AE SEM. Statistical analyses were performed using two-tailed Student's ttest or one-way ANOVA when appropriate. Fisher's least significant difference was used. Significance was set at *P < 0.05 using GRAPHPAD PRISM 6 software (La Jolla, CA, USA).
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